blog
News & Updates
Allosite Therapeutics to use generic name Ontegimod for its clinical lead
Miami, Florida, August 9th, 2023 — Allosite Therapeutics (DBA of 149 Bio, LLC) has announced its generic name for its clinical stage, lead candidate as Ontegimod (pronounced aun-teh-gi-mod). The company recently obtained rights to this molecule as part of its...
AlloSite Therapeutics launches
Miami, FL, August 8, 2023, (AllositeTx) – 149 Bio, LLC (DBA Allosite Therapeutics), a pioneering biotechnology company, announced launch of its updated website as Allosite Therapeutics. This strategic update reflects our focus on developing innovative therapeutics...
Acquisition of clinical stage integrin activator program from Gossamer Bio
149 Bio, LLC, a clinical-stage therapeutics company focused on developing breakthrough treatments for kidney diseases and other immune conditions with high unmet need, announced today that it has acquired GB1275, a first-in-class orally bioavailable integrin activator, and the associated CD11b program in its entirety from Gossamer Bio, Inc.
Nomination of integrin α3β1 as a target for its unique agonist antibodies as therapeutics for kidney disease
149 Bio, LLC has announced its therapeutic target for kidney diseases as integrin heterodimer alpha3beta1 (α3β1) that is highly expressed on kidney podocytes and is essential for podocyte attachment and health. The company also disclosed identification of novel allosteric agonist antibodies that target integrin α3β1 and enhance integrin-dependent ligand binding and cell adhesion.
© 2023 AlloSite Therapeutics. All rights reserved.